Please a sense of proportion's needed.
Who cares about the shorts? Are ALL of the instos playing games with them?
Surely not. Surely the oversubscribed bit is not hitting enough home, along with the new instos on board.
Perspective: Market conditions for biotechs is cut-throat right now, it's much tighter than the time of the Nasdaq listing when many new listings failed. We are in an extremely tight environment for raising capital. It's unbelievable how conservative lenders are being.
MSB goes to market with an offer and gets over-subscribed. What does that tell you?
Do those analysts have a clue? I think they do.
Shenanigans involving shorts is a side issue. Yes it affects the SP but LT we should be looking at how the company is stacking up.
Looking solid to me.
Ann: Mesoblast Completes Institutional Allocation, page-52
-
- There are more pages in this discussion • 212 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |